News from acacia pharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

Jan 04, 2018, 03:00 ETAcacia Pharma Announces FDA Acceptance of NDA Filing For BAREMSIS® for the Management of Post-operative Nausea & Vomiting

If approved, BAREMSIS would be the first antiemetic with an indication for: - rescue treatment of PONV after failed prophylaxis, and - combination...


Feb 13, 2017, 02:00 ETAcacia Pharma Announces Positive Results From its Fourth and Final Pivotal Trial of BAREMSIS™ for the Rescue Treatment of PONV

Extensive Phase 3 programme demonstrates clinical potential of BAREMSIS in rescue treatment and prophylaxis of PONV - NDA to be submitted to the US...


Aug 12, 2016, 03:00 ETAcacia Pharma Announces Positive Results From a Pivotal Phase 3 Trial of BAREMSIS™ for the Treatment of Post-Operative Nausea & Vomiting

BAREMSIS Now Shown to Treat PONV, as Well as Prevent it Acacia Pharma Group plc ("Acacia Pharma"), the supportive care company developing products...


Mar 21, 2016, 04:00 ETAcacia Pharma Initiates Second Pivotal Phase 3 Treatment Study with Baremsis™ (APD421) in Post-Operative Nausea & Vomiting (PONV)

NDA filing expected in second half of 2016 Acacia Pharma Group plc ("Acacia Pharma"), the supportive care company developing products for US and...


Jan 05, 2016, 03:00 ETAcacia Pharma Announces Positive Results from Second Pivotal Phase 3 Study of BAREMSIS™ (APD421) in Prevention of Post-operative Nausea & Vomiting

Acacia Pharma Group plc ("Acacia Pharma"), the supportive care company developing products for US and international markets, announces positive...


Dec 03, 2015, 04:00 ETAcacia Pharma: Dr Patrick Vink to Succeed Ian Kent as Non-Executive Chairman

Acacia Pharma Group plc ("Acacia Pharma"), the supportive care company developing products for US and international markets, today announces that Ian ...


May 06, 2015, 03:00 ETAcacia Pharma Announces Positive Results From Phase 2 Study With APD403 in Chemotherapy Induced Nausea & Vomiting (CINV)

- Primary Endpoint of Preventing Delayed CINV Met With High Significance Acacia Pharma Ltd ("Acacia Pharma" or "the Company"), a specialty...


Apr 21, 2015, 04:00 ETAcacia Pharma Initiates Phase 3 Combination Prophylaxis Study With APD421 in Post-Operative Nausea & Vomiting (PONV)

Acacia Pharma Ltd ("Acacia Pharma" or "the Company"), the supportive care company developing products for US and international markets, announces the ...


Oct 07, 2014, 03:00 ETAcacia Pharma Announces Positive Phase 3 Results For APD421 in Post-Operative Nausea & Vomiting (PONV)

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated...


Oct 30, 2013, 04:00 ETAcacia Pharma Initiates Phase II Study With APD403 in Chemotherapy Induced Nausea & Vomiting (CINV)

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of ...


Oct 15, 2013, 03:00 ETAcacia Pharma Announces Positive Phase II Results With APD515 for Xerostomia in Advanced Cancer

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces positive results from its Phase II...


Sep 17, 2013, 03:00 ETAcacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting (PONV)

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of two pivotal Phase 3 ...


Sep 03, 2013, 03:00 ETAcacia Pharma Raises £15 Million ($23.5 Million) to Advance Clinical Development of Lead Products for Supportive Care

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million (~$23.5...


May 28, 2012, 06:30 ETAcacia Pharma Announces Excellent Phase II Results for APD421 in Post-Operative Nausea & Vomiting (PONV)

Acacia Pharma announces positive results from its Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). The study...


Mar 31, 2011, 09:00 ETAcacia Pharma Closes $10 Million Investment Round

- Funds to be Used to Complete Two Phase II Programmes Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer...